In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux The post Merck cuts $1bn deal with Janux...
Roger Perlmutter Even as his tenure at Merck comes to a close, Roger Perlmutter isn’t finished wheeling and dealing just yet. Less than a month after...
Surface Oncology agreed to grant exclusive worldwide licensing rights to GlaxoSmithKline for the development and commercialization of the Cambridge, Mass.-based biotech company’s SRF813, a fully human...
It’s been a whirlwind week for Thermo Fisher. Over the course of five days prior to Wednesday, the Massachusetts CDMO had announced two major expansion projects...
Lexicon Pharmaceuticals has entered into a collaboration agreement with AC Bioscience, enabling the use of preclinical and clinical data for LX2931, without granting any right or...
Eli Lilly & Co. has inked an agreement to snap up Prevail Therapeutics for a total consideration of up to $1.04 billion, as the US drugmaker...
Harbour BioMed and Utrecht University licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its clinical program to AbbVie.
Synthetic DNA-encoded monoclonal antibodies make the recipient’s body the production plant Credit: The Wistar Institute PHILADELPHIA — (Dec. 15, 2020) — A team of scientists from...
With 2020 set to bring the curtain down on a biotech IPO boom unlike anything we’ve seen before, you have to wonder which companies are setting...
Markets have been turning mostly up since the election, as investors have taken the measure of the macro environment and appear pleased. There is some expectation...
Longenesis announces the first deployment of its flagship product Curator for real-time, privacy-preserving biomedical data identification, with National Research Programme in Latvia for COVID-19 research acceleration...
Syros Pharmaceuticals announced the acquisition of a clinical-stage drug candidate for Acute Promyelocytic Leukemia (or APL) from Orsenix, LLC. Syros (SYRS) has acquired from Orsenix all...
At the outset of 2020, Moderna (MRNA) was hardly a household name. But with 2021 in plain sight, the whole world is keeping a close watch...
First on CNBC: CNBC Transcript: Novavax President & CEO Stanley Erck Speaks with CNBC’s “Squawk Box” today, discussing the delayed U.S. Covid-19 vaccine trial. Q3 2020...
Expectations of good news on the near horizon are buoying markets right now. Over the past month, both the S&P 500 and the NASDAQ are up...
Maryland-based Altimmune Inc. has submitted an Investigational New Drug application to the U.S. Food and Drug Administration to commence a Phase 1 clinical study of its...
Vaccines are being touted as taking seven to ten years to develop. But you shouldn't be worried that COVID vaccines only took less than a year.
Merck acquired Maryland-based OncoImmune and the Covid-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during...
Shares of Avrobio plunged 17.6% on Friday after the clinical-stage gene therapy company kicked off a secondary offering of 5 million common shares. The offering is...
Top Value Creation Play In Biocare
Two K-State studies focus on SARS-CoV-2 transmission in domestic cats, pigs
Time to Make a Move? J.P. Morgan Offers 3 Stocks to Buy
Blood biomarkers for detecting brain injury in COVID-19 patients
Covid-19 roundup: EU begins reviewing Moderna vaccine; CureVac and EU agree to 405M-dose deal
News briefing: Locus Biosciences bags up to $12.1M for CRISPR antibacterial; Old Vertex drug heads to PhIII for dementia
Moderna: Ahead of COVID-19 Vaccine Data, This Analyst Stays Bullish
Oppenheimer’s Leland Gershell on the Future of Biopharma
Sanofi Picks Up Kiadis for $359 Million
Sean Bohen just wrote the handbook on how to make a quick fortune in biotech
3 Biotech Stocks in the Hunt for COVID-19 Vaccine; One Analyst Calls Them a 'Buy'